Concepedia

Author

David van Veenhuyzen

Shionogi (United States)

Also Known As

D. van Veenhuyzen, David Van Veenhuyzen, David van Veenhuyzen

12

Publications

496

Citations

5

H-Index

12

Concepts

All Affiliations

Shionogi (United States)Shionogi (Japan)
DV

About

David van Veenhuyzen is an author at Shionogi (United States) specializing in urology, sepsis, and antimicrobial resistance.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

413

2

Antibiotics

2

2

413

3

Health Sciences

1

1

26

4

Microbiology

1

1

26

5

Clinical Microbiology

1

1

26

David van Veenhuyzen

×

4

Publications

488

Citations

4

H-Index

YearCitations

Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial

Simon Portsmouth, David van Veenhuyzen, Roger Echols,

The Lancet Infectious Diseases

2018

387

Update on the Cardiac Safety of Moxifloxacin

Wilhelm Haverkamp, Frank Kruesmann, Anna Fritsch,

Current Drug Safety

2012

44

Moxifloxacin five‐day therapy versus placebo in acute bacterial rhinosinusitis

James A. Hadley, Ralph Mösges, Martin Desrosiers,

The Laryngoscope

2010

31

Clinical Response of Cefiderocol Compared with Imipenem/Cilastatin in the Treatment of Adults with Complicated Urinary Tract Infections with or without Pyelonephritis or Acute Uncomplicated Pyelonephritis: Results from a Multicenter, Double-blind, Randomized Study (APEKS-cUTI)

Simon Portsmouth, David van Veenhuyzen, Roger Echols,

Open Forum Infectious Diseases

2017

26

Page 1